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There is a lack of formal economic analysis to assess the efﬁciency of antimicrobial stew-
ardship programs. Herein, we conducted a cost-effectiveness study to assess two  different
strategies of Antimicrobial Stewardship Programs. A 30-day Markov model was developed
to  analyze how cost-effective was a Bundled Antimicrobial Stewardship implemented in a
university hospital in Brazil. Clinical data derived from a historical cohort that compared
two different strategies of antimicrobial stewardship programs and had 30-day mortality
as  main outcome. Selected costs included: workload, cost of deﬁned daily doses, length of
stay,  laboratory and imaging resources used to diagnose infections. Data were analyzed by
deterministic and probabilistic sensitivity analysis to assess model’s robustness, tornado
diagram and Cost-Effectiveness Acceptability Curve. Bundled Strategy was more  expensive
(Cost difference US$ 2119.70), however, it was more efﬁcient (US$ 27,549.15 vs 29,011.46).
Deterministic and probabilistic sensitivity analysis suggested that critical variables did not
alter ﬁnal Incremental Cost-Effectiveness Ratio. Bundled Strategy had higher probabilities
of  being cost-effective, which was endorsed by cost-effectiveness acceptability curve. As
health systems claim for efﬁcient technologies, this study conclude that Bundled Antimicro-bial  Stewardship Program was more cost-effective, which means that stewardship strategies
with such characteristics would be of special interest in a societal and clinical perspective.
©  2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
priate use of antibiotics, which is known to lead to worsentroductionntimicrobial stewardship programs (ASP) promote adequate
se of antimicrobial drug therapy (ADT) to infected patients.
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http://creativecommons.org/licenses/by-nc-nd/4.0/).They are meant to reduce undesired events due to inappro-clinical and economic outcomes, such as development of
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to increased ADT-related expenditures.1–4
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Nowadays, due to increasing health care costs, cost-
effectiveness analysis (CEA) are the watershed of many  health
systems, as they provide better planning, ﬁnancial and human
resources allocation.5
ASP economic outcomes have been analyzed with cost-
reduction studies and positive results due to decreased
antibiotics consumption6 and lower hospital length of stay
were observed. However, these results are controversial7,8 and
the ﬁnal outcome may be subject to many  confounders.6
Therefore, the incorporation of clinical data and sensitivity
analysis are necessary to assess whether one intervention
could lead to robust economic outcomes.
As a matter of fact, cost-reduction studies are not formal
economic analysis6 and, to our knowledge, there is only one
publication that investigated whether ASP are cost-effective.9
Furthermore, this single cost-effectiveness publication was
not free of bias, as there were many  theoretical assump-
tions when assigning clinical probabilities, leading to results
that could be unclear to clinicians due to complex reporting
and modeling methods. Moreover, the aforementioned CEA
employed diverse research outcomes (i.e. risk of death), while
costs were estimated from other health institutions and spe-
ciﬁc wards, such as critical care units.
Since 2001, some authors have been advocating that well
designed investigations with economic outcomes are needed,
especially on ASP.6,10 In addition, one recent publication has
suggested that different ASP strategies could lead to differ-
ent clinical outcomes. In that study, an ASP with proactive
characteristics lead to improved 30-day mortality results.11
In this context, considering that international literature
lacks direct comparison among ASP strategies, our hypothesis
was that different ASP strategies could also lead to differ-
ent economic outcomes. The objective of this research was
to assess whether two different ASP strategies could lead to
different performance results.
Methods
Ethics  and  reporting
The present study complies with Helsinki’s Declaration and
Local Bioethics Committee approved it. We followed the sug-
gestions of a Panel of Experts to conduct adequate reporting.4
Deﬁnitions  of  two  different  strategies:  conventional  and
bundled  ASP
This CEA compared two different modalities of ASP. We used
a previous cohort study that evaluated how Conventional or
Bundled ASP differed in terms of mortality and antibiotic
doses consumption.11
Conventional Strategy was deﬁned as a simpliﬁed steward-
ship program, which included a clinical pharmacist screening
for antimicrobial drug-related problem (ADRP), case dis-
cussions with infectious disease physicians (ID-MD) and
telephone-based interventions.
On the other hand, the Bundled ASP had a more  active
design, which included: prospective auditing and local edu-
cation/feedback about antimicrobial therapy prescription; 1 6;2  0(3):255–261
microbiological data discussion with laboratory personnel to
guide empirical or preemptive therapy; and face-to-face inter-
ventions to improve antimicrobial drug therapy.
Study  perspective  and  other  nation-related  issues
The perspective of this study was a Southern Brazilian Univer-
sity Hospital, which is a 550-bed public and clinical reference
institution with an average of 55–65% occupation rate. The
Brazilian Health-System, namely Sistema Único de Saúde (SUS),
is a primary care-centered system with universal access to all
Brazilian citizens. More information regarding the aforemen-
tioned health system should be consulted in excellent reviews
published elsewhere.12
Costs  and  deﬁnitions
All costs were collected and analyzed as local currency (R$,
Brazilian Reais) and converted to United States Dollars (US$).
Exchange values were collected at <reuters.com> and they
were expressed as mean value from February to September
2013, so R$ 1.00 was equivalent to US$ 0.47.
There were four relevant costs included in this CEA,
namely: (I) hospital length of stay/patient-day, (II) cost of
deﬁned daily doses (DDD)/patient, (III) resources to provide
microbiological and imaging diagnosis of infections, and (IV)
human resources workload per day. These variables were
collected through institutional databases, such as medica-
tion purchasing receipts and data from hospital’s Human
Resources and Planning Department. Table 1 summarizes all
costs accounted for in this study and supplementary material
provides detailed information.
Hospital length of stay was deﬁned as the average cost
per patient/day admitted to intensive care units or general
wards, which included water consumption, human resources,
medical material costs, and other relevant costs, except cost-
related to ADT (see supplementary material).
DDD is a validated tool to standardize the number of
doses consumed from each medication, allowing compari-
son of drug consumption between different health settings.
Therefore, DDD was collected according to the original
method developed by the World Health Organization.13 DDD
was calculated based on pharmacy dispensation registries.
Each unit of DDD was multiplied by the cost of drug,
so antimicrobial therapy was expressed as “cost-DDD per
patient”.13
Regarding the costs related to bacterial infections diagno-
sis, we deﬁned all diagnostic criteria according to international
guidelines.14–21 Prevalence of infections and their respective
topographies were collected from the same previous cohort
study,9 while costs of antibiograms, cultures, and other lab-
oratory and imaging methods were calculated by means of
microcosting bottom-up method.22
At last, cost of human workload per day was calculatedstaff involved with ASP, whereby Bundled ASP accounted for a
full-dedication clinical pharmacist resident and two  partially
dedicated ID physicians (one preceptor and one third-year
post-graduate MD).
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Table 1 – Summary of all included costs.
Average per patient Bundled ASP expenditures Conventional ASP expenditures
Cost (US$) Cost (US$)
Length-of-stay per daya 1457.35 1457.35
Antimicrobial consumption 1875.77 ± 107.05 4614.77 ± 174.15
Imaging or lab resourcesb 89.04 91.98
Cost of workload per dayc 92.79 45.33
DDD, deﬁned daily doses.
a The aforementioned table just illustrates the average value of length of stay per patient and mathematical modeling included individual
calculations,
b Values considered in mathematical model comprised individual calculations of image or lab resources and the aforementioned values are
only average costs per patient,
c Workload was expressed in this table as total ASP hours spend by day.
Notes: See Supplementary Material for more details about cost calculation.
Table 2 – The base case: outcomes, costs per patient, CER, and ICER.
Absolute Risk Direct costs (average value) CER ICER
Conventional ASP 0.6209 US$ 18,013.22 US$ 29,011.46
US$ 19,287.54
Bundled ASP 0.7308 US$ 20,132.92 US$ 27,549.15
Conventional ASPa 0.6202 ± 0.08 US$ 18,021.21 ± 5.72 US$ 29,057.10
US$ 19,317.58
Bundled ASPa 0.7328 ± 0.11 US$ 20,196.37 ± 6.33 US$ 27,560.55
t-Effectiveness Rate; ICER, Incremental Cost-Effectiveness Ratio.
ER represents the cost per incremental patient that survives 30 days.
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Notes: CER represents the cost per patient that survives 30 days. IC
linical  outcomes  (effectiveness)
ransition probabilities among health states were obtained
hrough effectiveness data.11 For both strategies, we compared
0-day mortality, which was expressed as either time-to-event
ata or point estimate value: Absolute Risk Rate (AR), Risk
ifference (RD), and Number Needed to Treat (NNT) (Table 2).
Survival probabilities through each day (out of 30-day mor-
ality) were also obtained from the same previous cohort.11
ata  analysis
ata were analyzed by comparing both strategies in the base
ase, by reporting crude costs, clinical outcomes, and efﬁ-
iency indicators such as: Cost-Effectiveness Rate (CER) and
ncremental Cost-Effectiveness Ratio (ICER).
Thereafter, costs and effectiveness variables were modeled
y using TreeAge Pro 2009 Suite Software (TreeAge Soft-
are Williamstown, MA,  USA). A health-transition model was
eveloped to simulate the probability of patients to make
ransitions between two health states (alive or death). We
eveloped a Markov process in order to make the model sen-
itive to changes that might occur from one day to another.
he aforementioned model consisted of 30 cycles aligned to
0-day mortality outcome. Each cycle-length corresponded
o one day. Fig. 1 illustrates the model adopted in this
tudy.
A deterministic one-way sensitivity analysis was con-
ucted to identify whether variables range could critically
nﬂuence the ﬁnal ICER. Because binary variables cannot be
ssessed within this method, this sensitivity analysis did not
nclude clinical outcomes, but only costs.Fig. 1 – Markov process.
Multivariate analysis was performed by 2nd order Monte
Carlo technique that simulated 10,000 probabilistic iterations.
This analysis tested whether large ranges and their 95% con-
ﬁdence intervals could disturb the ﬁnal ICER.
All cost variables were analyzed as Gama distributions and
hyperparameters were calibrated to a 95% probability interval.
Beta distributions were applied for effectiveness probabilities.
Finally, a tornado diagram illustrated one-way analysis,
while Cost-Effectiveness Scatterplot, Acceptability Curve of
Cost-Effectiveness and ICE Scatterplot showed the results
from probabilistic sensitivity analysis. Discounting was not
applied in the model since the horizon corresponded to one
month; however, half-cycle correction was applied for all prob-
abilistic iterations.23
ResultsThe  base  case
In a preliminary analysis, the Bundled ASP was more  expen-
sive than a conventional ASP (Table 2) and the difference of
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Incremental Cost/Eff
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Fig. 2 – Tornado diagram with critical variables. Notes:
Vertical line represents ﬁnal ICER. Critical variables are
represented as horizontal bars. All variables crossed ﬁnal
ICER, which means that none of them were able to disturb
the ﬁnal result from base case. c obs-otim intern, length of
stay cost; c otim equipe, Bundled Strategy human
resources cost; c obs medct, antimicrobial cost in
Conventional Strategy; c c otim medct antimicrobial cost
in Bundled Strategy; c obs dx inf, bacterial infections
diagnostic cost in Conventional Strategy; c otim dx inf,
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Fig. 3 – Scatterplot with 10,000 virtual cohorts. Note: Each
dot represents one virtual cohort, thus, Bundled Strategy is
likely to be more  effective (y axis) and at similar costs
institution.bacterial infections diagnostic cost in Bundled Strategy.
crude costs was US$ 2119.70/patient. Considering point esti-
mate values, which are expressed as Absolute Risk, Bundled
ASP was more  effective and patients are more  likely to survive
(73.1% vs 62.1%, p < 0.05).
Nevertheless, by observing health economic indicators
(CER) the base case suggests that Bundled Strategy was more
cost-effective, which was also seen after 10,000 virtual sim-
ulations. Finally, ICER suggests that each averted death in 30
days costed US$ 19,287.54.
Deterministic  sensitivity  analysis
ICER did not change when confronting the aforementioned
base case results against critical variables. Therefore, accord-
ing to one-way deterministic analysis, previous ICER was
robust (Fig. 2). We  observed that length of stay cost, human
resources, and antimicrobial consumption were the critical
variables that had the greatest ICER range.
Probabilistic  sensitivity  analysis
Probabilistic sensitivity analysis showed that ICER was robust.
Scatter Plot graph shows that Bundled Strategy stayed clini-
cally superior and at similar costs compared to the other group
(Fig. 3).Finally, Cost-Effectiveness Acceptability Curve (CEAC)
(Fig. 4) was used to assess whether Bundled ASP would be
affordable in the perspective of the studied health institution.(x axis).
We  observed that Bundled ASP has higher probability of
being the most effective (C1 + C2 + C4 = 92.7%) and the most
cost-effective strategy (C1 + C2 vs C4 = 52.6% vs 40.1%).
When ICER was set as Willingness-To-Pay function (diago-
nal line represents stakeholders’ cutoff), Acceptability Curve
demonstrated higher probabilities of Bundled Strategy stay
under stakeholders’ willingness-to-pay. These results corrob-
orated with previous base case and deterministic analysis.
Discussion
CEA analysis is an interesting tool to improve health systems’
performance, so decision-makers can assess and incorporate
one technology that is the most cost-effective. In our study, we
found that Bundled ASP Strategy was effective, efﬁcient and
at affordable costs, even after 10,000 probabilistic iterations.
Relevant  costs  and  effectiveness
Due to our close relation to Planning Department, it was possi-
ble to collect speciﬁc data and assemble them in our economic
modeling. Microcosting bottom-up method required time and
may not be feasible to other institutions, but still is a reliable
way to collect costs.
Previous CEA that assessed the efﬁciency of one ASP9 used
similar modeling and data analysis. The difference between
this and past study is that previous publication included mul-
tiple setting clinical probabilities and costs. We  also observed
that some data derived from 1999, but manuscript was pub-
lished in 2009.
Costs from other settings and inclusion of clinical
outcomes from different institutions constitute the main
drawback from previous publications. To avoid such bias, we
believe that the present study has overcome these problems
by considering expenditures and clinical data from a single
11Different ASP interventions were never compared
regarding their efﬁciency, and international literature lacks
direct comparison between ASP strategies.
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Fig. 4 – Cost-Effectiveness Acceptability Curve (CEAC) between Bundled and Conventional ASP.
Component Quadrant Incremental effectiveness Incremental cost ICER # of dots %
C1 IV IE > 0 IC < 0 Superior 3414 34.14
C2 I IE > 0 IC > 0 <ICER 1851 18.51
C3 III IE < 0 IC < 0 >ICER 351 3.51
C4 I IE > 0 IC > 0 >ICER 4013 40.13
C5 III IE < 0 IC < 0 <ICER 222 2.22
C6 II IE < 0 IC > 0 Inferior 149 1.49
Quadrants are read as “I” (upper right, the most effective and expensive), “II” (upper left, the less effective and the most expensive), “III” (lower left,
the less effective and less expensive strategy) and “IV (lower right, the best scenario with higher probabilities of effectiveness at lower costs).
Diagonal line represents Willingness to Pay Function (WTP) and all virtual cohorts under this curve were considered affordable by the studied
health institution.
“Component” represents a group of representative dots in CEAC. C1 and C2 represent that Bundled strategy is, respectively, dominant and under
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(b) for every US19,000 dollars invested, one will experienceTP function. C4 represents the probability (40%) that Bundled Strateg
f all iterations) are less representative probabilities and account for le
One could notice that Bundled ASP resembles other pub-
ished and practiced stewardships with multiple types of
nterventions11 and, therefore, at this viewpoint, external
alidity is one of the positive aspects of our clinical effective-
ess probabilities.
arkov  model  and  accuracy  of  this  study
nstead of choosing a Decision Model Tree, which is com-
only used to acute care conditions, Markov Model provides
ore accuracy for each of the 30-day probabilities. Markov
odel could precisely estimate the probability of one patient
o die or to survive each day: costs quantiﬁcation is dependent
n accumulative probabilities of surviving or dying. In other
ords, if one patient survives, there would be an accumu-
ative cost in the next day; likewise, if one patient dies, it
ould probabilistically reduce cost-effectiveness ratio. Previ-
us publications9 included a decision tree analysis, and due
o the aforementioned reasons, they were poorly planned and
ould have methodological bias.
With respect to internal validity, patients should be
linically compared and primary site of infection may be insuf-
cient to determine if groups are homogeneous.9 In a previous
tudy, multivariate analysis determined that Charlson Comor-
idity Index could independently predict mortality in patients
ssisted by ASP.11 The known association between Charlson
omorbidity Index and Mortality impacts previous study’s
ist of assumptions9, where it was stated that “patients who
ever received an active antimicrobial drug therapy would
ave twice as poor outcomes (die twice) as those receiving an
ctive therapy”. In other words, when deﬁning an economicore expensive and above WTP function. C3, C5 and C6 (less than 10%
ective and more expensive percentages.
model, we  should attempt to choose evidence-based probabil-
ities of mortality to accurate predict real cost-effectiveness of
ASP.
Other  relevant  interpretations
CEAC analysis was never performed before in other ASP
research. It is a comprehensive way to help those who are
not familiar with economic assessments to understand CEA.
Nevertheless, to conduct such analysis, we  set how much
stakeholders would need to pay to have one Bundled ASP,
by considering its structure, clinical and economic outcomes.
Herein, we suggested ICER as the Willingness to Pay value
(US 19,000 dollars per patient who survived 30-day mortality
outcome).
ICER was determined as cut off value, because direct or
indirect ways of deﬁning “Willingness to Pay” are not vali-
dated and are subject to criticism. In addition, clinicians and
stakeholders may interpret it more  properly if NNT is also
incorporated.
Therefore, by considering ICER value and that Bundled ASP
has a NNT = 9, we suggest the following interpretations:
a) for every nine patients treated, one will beneﬁt (or achieve
30-day outcome);the beneﬁt;
(c) as NNT and ICER conceptions are similar, every nine
patients treated will cost US19,000 dollars and one will
have positive clinical outcome.
i s . 2 0
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Limitations
Our study is not free of limitations. The present study used
effectiveness probabilities from a historical cohort, which
means that retrospective data collection should always be
cautiously interpreted due to incomplete registries, censoring,
and research blinding problems.
Moreover, as two different ASP strategies were rarely com-
pared in literature, more  studies should be performed to
assess if previous epidemiological ﬁndings (base case) are
reproducible. When interpreting our results, one should con-
sider the population included in the previous study, which was
based on general wards and intensive care units inpatients.11
Other health settings should adapt this information before
extrapolating our results to different practice scenarios.
Although sensitivity analysis corroborated with base case,
cost-effectiveness should always consider one perspective.
Readers should be aware of our study’s external validity, espe-
cially because it was conducted in a Latin American health
service, and differences are notorious between health systems
and clinical settings.
Finally, although we believe that relevant costs were
included in our economic modeling, ICER and Willingness-to
Pay are not interchangeable concepts. In the present study,
we did so because base case was a retrospective study, so
all expenditures were already paid by hospital’s ﬁnancial
department. Therefore, we considered that all values under
Willingness-to Pay function would be affordable.
Conclusion
Bundled ASP was more  cost-effective and also associated
with higher probabilities of clinical success and at reasonable
implementation costs, while conventional ASP was a cheaper
strategy but less efﬁcient. Therefore, (I) stakeholders should
be aware to our critical variables (length of stay and human
resources costs), before implementing an ASP; (II) patients
would receive all advantages from a healthcare program that
promotes better outcomes; (III) economic assessments are still
sparse in literature, so we  wish our study could motivate other
researchers to conduct other ASP formal economic analyses.
Finally, our results should be assessed in other settings and
countries. Future stewardship researches should made efforts
toward coupling well conducted clinical and epidemiological
studies, as backbones of economic analysis, once there is a
special interest on incorporating high performance technolo-
gies to health settings and systems.
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